The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
CCL
Vol.
27
No.
8
August 27, 2004
- ASCO Recommends Against Routine Adjuvant Chemo For Stage II Colon Cancer
- Exercise Improves Function, Symptoms Of Cancer Survivors, AHRQ Report Finds
- Guideline Adherence Improves Early Breast Cancer Survival
- Chemosensitivity, Resistance Assays Not Ready For Clinic, ASCO Tech Assessment Says
- FDA Approves Taxotere For Node+ Breast Cancer
- FDA Approves Lilly’s Alimta For Metastatic NSCLC
- Reduced Risk of Metastasis When Screening Finds Cancer
- Ellence Has Lower Risk Of Heart Damage, Study Finds
- Modality Combo Decreases Prostate Cancer Recurrence
- Hormonal Therapy Improves Prostate Cancer Survival
- Study Suggests Surveillance Colonoscopies Overperformed
TCL
Vol.
30
No.
35
September 17, 2004
- Advisors to NCI are preparing to recommend a “Human Cancer Genome Project” that would create a comprehensive chart of the genetic mutations that cause cancer. The panel also plans to propose an initiative in molecular diagnostics, Eric Lander, director of the Broad Institute, said.
- Also in this 8-page issue: White House appoints Koch Industries executive David Koch to the National Cancer Advisory Board. He asks: “How can we make the NCI elephant dance like a ballerina?”
- Funding opportunities listed.
TCL
Vol.
30
No.
36
September 24, 2004
- PR firm Ketchum serves two clients on Medicare issues: CMS and ASCO. HHS policy officials weren’t told about potential conflict, department spokesman says.
- Also in this 8-page issue: NIH opens 240-bed Hatfield Clinical Research Center.
- NCI Clinical Trials Working Group is looking for pragmatic solutions to improve cancer clinical trials system, Institute official says.
- NCI expands program to promote healthy diet among African Americans.
- UPCI wins NCI SPORE grant for head and neck cancer.
- Funding opportunities listed.
CCL
Vol.
27
No.
9
September 24, 2004
- New Approaches To Improve Diagnoses In Urogenital Cancers Presented At AUA
- Younger Patients, More Advanced Stages, More Likely To Die From Breast Cancer
- MRI Effective For Women With BRCA Gene Mutations
- Study Supports Immediate Breast Reconstruction
- UC Davis Is U.S. Site For Trial Of Exemestane For Breast Ca.
- Surgery, Radiation Effective For Older Women, Study Finds
- Immune Therapy Possible For Metastatic Breast Cancer
- PET Tracer Drug Approved, Developed At Weill Cornell
- Clinical Trials Approved By NCI Listed For September
TCL
Vol.
30
No.
37
October 01, 2004
- Institute for Cancer Prevention, of Valhalla, N.Y., last week closed its doors and sought protection under bankruptcy laws after NCI alleged that the center improperly withdrew $5.7 million in federal funds. IFCP, formerly known as American Health Foundation, had ample warning of its fiscal crisis, NCI said.
- Also In sudden policy change, NIH proposes one-year ban on consulting by employees.
- Senate committee approves $1.1 billion increase for NIH.
- NIH selects nine scientists for Pioneer Awards.
- DoD Ovarian Cancer Research Program seeks proposals for FY05 funding.
- September issue of Business & Regulatory Report included–8 additional pages of industry news.
TCL
Vol.
30
No.
38
October 08, 2004
- New guidelines for Cancer Center Support Grants will enable centers to apply for salary support for clinical investigators.
- New benchmark for CCSG award funding will be lowered from 20 percent of NCI research base to 15 percent, the program’s “reality ratio,” Karen Antman tells NCAB.
- Also in this 8-page issue: FDA begins search for director of new Office of Oncology Drug Products.
- Broad Institute wins NIH grant for first national SNP genotyping center.
- Cancer center investigators share Nobel Prizes in medicine, chemistry.
- Funding opportunities listed.
TCL
Vol.
30
No.
39
October 15, 2004
- Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.
- Also in this 8-page issue: NCI closes its Tobacco Intervention Research Clinic, blaming flat budget, slow accrual.
- Hope for FDA authority over tobacco products dies in Congress.
- Patients urge Medicare to allow an open formulary for cancer treatment.
- Promotions at MSKCC: Fuks heads radiation oncology, Pfister named chief of Head & Neck Medical Oncology Service.
- Funding opportunities listed.